Megha Patel
Internal Medicine · Chicago, ILNPI 1962984773
Payments from drug & device makers
Across 329 payments — averaging $22.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$954
- Boehringer Ingelheim$875
- AbbVie$581
- Corcept Therapeutics$452
- Novo Nordisk$347
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,550100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 73 | $1,826 |
| Lilly USA, LLC | 61 | $954 |
| Boehringer Ingelheim | 37 | $875 |
| AbbVie | 22 | $581 |
| Corcept Therapeutics | 11 | $452 |
| Novo Nordisk | 15 | $347 |
| Amgen | 17 | $336 |
| Pfizer | 14 | $328 |
| Bayer | 10 | $288 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $184 |
| Merck | 8 | $148 |
| Exact Sciences | 5 | $142 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $127 |
| Johnson & Johnson | 4 | $106 |
| Biohaven Pharmaceuticals, Inc. | 4 | $102 |
| UCB, Inc. | 1 | $101 |
| Sanofi-aventis U.S. LLC | 3 | $70 |
| GSK | 3 | $66 |
| Seqirus USA Inc | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 2 | $48 |
| Eisai Inc. | 2 | $46 |
| Radius Health, Inc. | 2 | $45 |
| Avion Pharmaceuticals | 3 | $44 |
| Azurity Pharmaceuticals, Inc. | 2 | $40 |
| Arbor Pharmaceuticals, Inc. | 2 | $37 |
| Novartis | 2 | $36 |
| Ardelyx, Inc. | 1 | $33 |
| Redhill Biopharma Inc. | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Dexcom, Inc. | 1 | $25 |
| Gilead | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,550 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 37 | $51,966 |
| FarxigaDapagliflozin Propanediol | 28 | $40,569 |
| OzempicSemaglutide | 20 | $34,398 |
| TradjentaLinagliptin | 28 | $33,558 |
| TrulicityDulaglutide | 21 | $24,760 |
| MounjaroTirzepatide | 20 | $21,774 |
| JanuviaSitagliptin Phosphate | 12 | $15,121 |
| EliquisApixaban | 13 | $12,727 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,220 |
| Dexlansoprazole DrDexlansoprazole | 11 | $5,885 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,371 |
| Atorvastatin Calcium | 114 | $1,243 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $1,078 |
| Rosuvastatin Calcium | 47 | $1,045 |
| Metformin Hcl | 108 | $804 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $875 | $85,52465 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,826 | $51,78846 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $954 | $46,53441 claims |
| Novo NordiskOzempic | $347 | $34,39820 claims |
| MerckJanuvia | $148 | $15,12112 claims |
| PfizerEliquis | $328 | $12,72713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Chicago
- Dennis LevinsonChicago$25.3M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Mohammed KassemChicago$1.3M
- David BakerChicago$1M
- Azazuddin AhmedChicago$912K
- Daniel BergerChicago$861K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.